Skip to main content

Table 1 Representative molecular imaging agents developed for c-MET imaging in cancer

From: Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review

Name Nature Molecular weight (kDa) Targeted area Tumor model Tumor uptake T/C Imaging technique Time point Clin
64Cu-NOTA-rh-HGF rh-ligand ~90 Extracellular U87MG 6.8 ± 1.8%ID/g T/M =13.5 ± 6.1 PET 9 h p.i. No
125I-mAb mAb ~150 Extracellular S114 T/TB = 0.37 Gamma camera 3 days p.i. No
125I-Met3 mAb ~150 Extracellular S114, SK-LMS-1/HGF 18.6 ± 2.1%EIA,
7.2 ± 2.2%EIA
T/TB = 0.32 ± 0.13, T/TB = 0.168 ± 0.076 Gamma camera 3 days p.i., 6 days p.i. No
125I-Met5 mAb ~150 Extracellular SK-LMS-1/HGF 13.3 ± 7.6%EIA, T/TB = 0.146 ± 0.097 Gamma camera 1 day p.i. No
125I-hFab-Met-1 Fab fragment ~60 Extracellular SK-LMS-1/HGF 6%EIA Gamma camera 5 h p.i. No
125I-MET4 mAb ~150 Extracellular SK-LMS-1/HGF Gamma camera 3 days p.i. No
89Zr-DN30 mAb ~150 Extracellular GTL-16 19.6 ± 3.3%ID/g T/M = 17.5 PET 3 days p.i No
89Zr-df-onartuzumab mAb ~99 Extracellular MKN-45 23%ID/g T/M = 27 PET 3 days p.i No
89Zr-DFO-H2cys-diabody scFv ~55 Extracellular Hcc827-GR6 3.4 ± 0.3%ID/g T/M =27 ± 14 PET 44 h p.i. No
Ms20-QD scFv ~25 Extracellular H1993 T/Tn = 4.3 NIRfluorescence 24 h p.i. No
anti-MET-Gd-DTPA-albumin mAb ~150 Extracellular C6 SIC(T/Tn) ≈ 5 MRI 3 h p.i. No
SPIO-anti-c-MET PcAb ~150 Extracellular CDAA-HCC SIC(T/Tn) ≈ 2 MRI 1.5 h p.i. No
125I-Met-pep1 Peptide ~1.5 Extracellular SK-LMS-1/HGF 5%EIA, Gamma camera 4 h p.i. No
125I-cMBP-GGG Peptide ~1.9 Extracellular U87MG 7.05 ± 1.2%ID/g T/Bl = 2.94 SPECT 4 h p.i. No
cMBP-AOC-Cy5.5 Peptide ~2.8 Extracellular U87MG T/M =33.711 ± 3.34 NIRfluorescence 5 h p.i. No
GE-137 Peptide ~4.2 Extracellular SKOv3 T/Ba = 1.6 NIRfluorescence 3 h p.i. Yes
18F-AH113804 Peptide ~3.2 Extracellular HCC1954 1.5 ± 0.2%ID/ml T/M ≈ 2 PET 1 h p.i. No
99mTc-AH113018 Peptide ~3.2 Extracellular MKN-45 10.1 ± 1.5%ID/g T/M =55.2 ± 13.4 SPECT 1.5 h p.i. No
89Zr-PRS-110 s-protein 57 Extracellular H441 7.5 ± 3.4%ID/g T:M = 29 PET 48 h p.i. No
11C- SU11274 smTKI ~0.6 Intracellular H1975 SUV = 0.45 T/TN = 2.6 PET 1.3 h p.i. No
  1. Tumor model major positive tumor model, Tumor uptake highest tumor uptake in major positive tumor model, T/C tumor control area activity ratio, Time point optimal imaging time point, Clin clinical transformation, %EIA percentage of estimated injected activity, SUV standard uptake value, T/M tumor to muscle, T/TB tumor to total body, T/T n tumor to tumor with non-specific probe, SIC signal intensity changes, T/Bl tumor to blood, T/Ba tumor to background fluorescence, T/T N tumor to negative tumor